This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

Invasive Fungal Infection (IFI)

Updated on 24/01/2019

ANTI-FUNGALS

Invasive fungal disease (IFD), is associated with high morbidity and mortality.1 Invasive fungal infections (IFI’s) are those infections where fungi have invaded in to the deep tissues and have established themselves resulting in prolonged illness. IFI’s usually are seen in debilitated and immunosuppressed individuals.2

Who is at risk?

The below image depicts which patients are at high, medium and low risk of developing an invasive fungal infection, according to Pagano et al (2011)2. Those at highest risk of developing an invasive fungal infection are those receiving remission-induction chemotherapy for Acute Myeloid-Leukemia or those undergoing an allogeneic haematopoietic stem cell transplantation (HSCT).

Underlying condition and fungal risk2

Image showing underlying condition and fungal risk

What are the risk factors?

The below image, adapted from ECIL 5 (2013) depicts the risk factors for invasive fungal infection. For these patients, ECIL-5 recommends the following preventative measures:

  • Avoid construction / renovation activities as well as heavily contaminated items (such as plotted plants, soil, pepper,…)
  • Protective isolation with HEPA-filtration to prevent exposure
  • Mould-active azole prophylaxis to prevent disease3

Risk factors for invasive fungal disease in AML and MDS undergoing AML-like chemotherapy3 (adapted from ECIL 5, 2013)

Image showing risk factors for invasive fungal disease in AML and MDS undergoing AML-like chemotherapy

Related Content

 

References

  1. Ramana et al. American Journal of Infectious Diseases and Microbiology. 2013; Vol. 1, No. 4, 64-69.
  2. Pagano et al. J Antimicrob Chemother. 2011;66 Suppl 1:i5-14.
  3. ECIL 5 guidelines, European Conference on Infections in Leukaemia, 2013. www.kobe.fr/ecil/telechargements2013/ECIL5antifungalprophylaxis%2020062014Final.pdf.

Supporting documentation

100 mg Tablets
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

300 mg IV
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

40 mg/ml Oral Suspension
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-POS-00029 | Date of Preparation: January 2019